Who Generates Higher Gross Profit? Takeda Pharmaceutical Company Limited or Pharming Group N.V.

Takeda vs. Pharming: A Decade of Gross Profit Dominance

__timestampPharming Group N.V.Takeda Pharmaceutical Company Limited
Wednesday, January 1, 2014215951651256834000000
Thursday, January 1, 201565904271271973000000
Friday, January 1, 2016117685421173296000000
Sunday, January 1, 2017925870381274610000000
Monday, January 1, 20181292038431437534000000
Tuesday, January 1, 20191654124472201424000000
Wednesday, January 1, 20202030564302203504000000
Friday, January 1, 20211696700712462160000000
Saturday, January 1, 20221880600002783406000000
Sunday, January 1, 20232201040002832257000000
Monday, January 1, 20242832257000000
Loading chart...

Igniting the spark of knowledge

A Tale of Two Pharmaceutical Giants: Gross Profit Analysis

In the competitive world of pharmaceuticals, understanding who leads in financial performance is crucial. This analysis compares the gross profit of Takeda Pharmaceutical Company Limited and Pharming Group N.V. from 2014 to 2023. Over this period, Takeda consistently outperformed Pharming, with gross profits reaching a staggering 2.8 trillion in 2023, a 125% increase from 2014. In contrast, Pharming's gross profit, while growing, peaked at 220 million in 2023, marking a significant rise from 2014 but still a fraction of Takeda's figures. This stark contrast highlights Takeda's dominant market position and robust financial health. However, Pharming's growth trajectory suggests potential for future expansion. Missing data for 2024 indicates the need for ongoing analysis to capture future trends. This financial narrative underscores the dynamic nature of the pharmaceutical industry and the importance of strategic growth.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025